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Summary: 
Title:  “THE PREVALENCE OF CARDIOVASCULAR RISKS IN HIV-INFECTED 
PERSONS IN CARE IN CROATIA IN 2015.” 
Author: 
Ivan Desbordes 
 
Abstract: 
Aim:This review will aim at considering the prevalence of cardiovascular risks among 
the HIV-infected population undergoing ART therapy in Croatia: Cardiovascular 
diseases are now among the most common causes of mortality in people living with 
HIV. We will see for which reasons people living with HIV appear to have an elevated 
risk for cardiovascular diseases.  
Method: A cross-sectional analysis of 310 consecutive HIV infected patients seen 
during a routine clinical visit aged 40 to 79 years was performed in Zagreb  from June  
2014 to March 2016. All the next cardiovascular risks factors were systematically 
assessed: age, gender, race, total cholesterol, HDL cholesterol, triglycerides, systolic 
blood pressure, diastolic blood pressure, smoking, diabetes(blood glucose 
measurements), treated for high blood pressure (yes or no), past and current history 
of ART (particularly, duration of treatment including abacavir, indinavir and lopinavir 
(DAD)). Were also systematically collected  CD4+ cell count, HIV viral load, family 
history of premature CVD, past medical history of CVD. 
Results: Among the 310 persons included into the study, 42% were current smokers, 
23% were hypertensive, 34% had Hypercholesterolemia (>6.2 mmol/L), 38% of 
patients were overweight, 12% were obese, 27% exhibited metabolic syndrome, 
7.8% of patients had past cardiovascular event, 12.9%  patients had a family history 
of premature cardiovascular event, 21% of patients were already treated for high 
blood pressure, 18.4% were already treated with lipid-lowering agents, 46% of the 
studied population had an abacavir-including antiretroviral regimen, 10% of patients 
had a detectable viral load, and 11.6% of patients had a low CD4+ cell count (<350 
per mm3). 
Conclusion : : Among the HIV-infected persons in care in Croatia in 2015, the 
prevalence of a compound collection of major cardiovascular risk factors is high.  
 
Key words: ART dyslipidemia prevalence cardiovascular risk Croatia 
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INTRODUCTION 
The introduction of highly active antiretroviral therapy (HAART) combinations for 
human immunodeficiency virus (HIV)-infected patients, which was for the first time 
able to effectively suppress the replication of HIV  and dramatically reduce  both 
mortality and morbidity, has resulted  in a better and longer quality of life for HIV-
patients [1]. These innovative combinations have dramatically changed their life’s 
perspectives [2]. 
The different ART combinations, all composed of at least three different antiretroviral 
drugs, can manage to reduce viral load to undetectable levels [3]. ART combinations 
prevent viral replication by acting at different stages of the viral replication cycle [4]. 
They are classified in different therapeutic groups according to their action’s 
mechanism: integrase strand transfer inhibitors (InSTIs) [5], entry inhibitors [CC 
chemokine receptor-5 antagonists][6], fusion inhibitors [7], protease inhibitors 
(PIs)[8], nonnucleoside reverse transcriptase inhibitors (NNRTIs)[9] and nucleoside 
reverse transcriptase inhibitors (NRTIs)[10]. Aside from the substantial benefits on 
viremia that result from the use of various  ART combinations, laboratory and clinical 
experience has shown that  ART can induce severe and considerable adverse effects 
on metabolic complications of lipid metabolism, characterized by signs of 
lipodystrophy, insulin resistance, central adiposity, dyslipidemia, increased risk of 
cardiovascular disease and even an increased risk of atherosclerosis [11-14]. 
Noteworthily, other individual factors may be involved in the metabolic and lipid 
alterations observed because not all of the patients exposed to the same ART 
regimens are similarly affected [15-17]. All of these changes in the aspects of lipid 
metabolism during HIV infection, specifically changes in high-density lipoprotein 
cholesterol (HDL), low-density lipoprotein cholesterol (LDL), very low-density 
lipoprotein cholesterol (VLDL), triglycerides (TG), lipid peroxidation, and their 
relationship with atherosclerosis in HIV-infected patients, are a result of the critical 
role of cholesterol in the mechanism of HIV replication [13,14,18,19]. HIV decreases 
plasma HDL by impairing the cholesterol-dependent efflux transporter ATP-binding 
cassette protein A1 in human macrophages, which is a condition that has a high 
atherogenic risk [20,21].  
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ART-associated lipid disorders: 
Cardiovascular risk associated to PIs regimens 
The use of PI-based ART constitutes a strong option against HIV infection because it 
prevents both the maturation of viral particles and controls the infection of new cells 
by HIV. Unfortunately this virological efficiency often goes along with changes in lipid 
metabolism in HIV patients and dyslipidemias have been associated with this class of 
antiretroviral drugs [11,12,22,23]. PIs are associated with increased hepatic 
triglycerides-synthesis, VLDL, and to a lesser extent, total cholesterol (TC) [11-14]. It 
has also been observed that these drugs impair the hydrolysis of triglyceride-rich 
lipoproteins by lipase, which reduces the storage of free fatty acids and interferes 
with the normal postprandial metabolism of free fatty acids [22,24]. The PIs are 
analogous substrates of the aspartyl protease enzyme of HIV that are involved in the 
cleavage process of viral proteins and form smaller functional viral particles with 
infective capacity. After the cleavage process, the newly formed infectious viral 
particles are released from infected cells in a mature form [8,25,26]. Once the PIs 
bind to the active site of the protease enzyme, and this process of cleavage is 
blocked, there is interference in the enzyme activity and inhibition in the process of 
viral maturation and the formation of infectious viral particles [25,26]. The different 
mechanisms by which PIs promote these changes remain unknown. However, the 
main effect of PIs seems to be suppressing the breakdown of the nuclear form of 
sterol-regulatory element binding protein-1 in the liver and adipose tissue. This 
regulator is a key element in the proteolytic pathway responsible for regulating 
cellular and plasma levels of fat and cholesterol [27].  
Of course, other classes of antiretroviral drugs are available, including those with 
excellent activity against viral replication without having any apparent effect on lipid 
metabolism [13,22,28]; but it is clear that the use and recommendation of PIs occurs 
in situations where other drugs have not achieved the targeted effect, either by 
nonadherence to treatment, viral resistance or lack of an immune response [29,30]. 
Moreover, once the therapy with PIs is initiated, a change to a more conservative 
therapy without their use is not recommended nor used in clinical practice [31,32]. 
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Thus, a continuous search that considers the individual characteristics of each PI 
available as a current therapy is needed to achieve alternative ARTregimens that can 
maintain a suppression of viremia with minor effects on the lipid metabolism of HIV 
patients [31,33]. 
 
Cardiovascular risk associated to NRTIs 
Evaluation of the potential contribution of nucleos(t)ide reverse transcriptase 
inhibitors (NRTI)  on the increased cardiovascular risk in HIV patients on ART within 
the D:A:D study revealed an increased risk for myocardial infarction in patients being 
treated with abacavir or exposed to this drug within the preceding 6 months was 
reported for the first time [34]. These findings were confirmed by several studies, but 
not all: A french study based on Hospital database short-term/recent exposure to 
abacavir was associated with an increased risk of myocardial infarction in the overall 
cohort [odds ratio (OR) 2.01; 95% confidence interval (CI), 1.11–3.64] but not in the 
subset of matched cases and controls who did not use cocaine or intravenous drugs 
(OR:1.27; CI: 0.64–2.49). This has raised the question as to how far cohort studies 
can adjust for all potential confounding factors which may contribute to 
cardiovascular risk and which may have been over-represented in the abacavir-
treated patients.  
With regard to other NRTIs no increased risk has been found. Table 1 summarizes 
the main classes of antiretroviral drugs, their effects on lipid and glucose metabolism, 
and the potential for contributing to the risk of CVD. Azidothymidine, a NRTI and 
component of first line ART, has been described to cause cardiac dysfunction 
induced by mitochondrial toxicity [35,36] in two reports on adults, where three larger 
studies could not confirm any association between exposure to azidothymidine and 
myocardial dysfunction [37-39]… 
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Cardiovascular risk associated to NNRTIs 
If Protease inhibitors (PIs) are recognized as having the greatest impact in terms of 
metabolic complications, followed by nucleoside reverse transcriptase inhibitors, the 
non-nucleoside reverse transcriptase inhibitors (NNRTIs) have the least impact [40] 
and appear to be among the most neutral regarding metabolic changes 
(dyslipidemias and glucose regulation impairment). In particular, regimens based on 
the NNRTI nevirapine have been shown to achieve significant metabolic benefits and 
may help to improve dyslipidemias. 
Table1: Main Classes of antiretroviral drugs and their impact on lipid and glucose metabolism and coronary artery 
disease. Dyslipidemia is defined by increased TC, LDL, TG and decreased HDL. MI, myocardial infarction. [41 ] 
 
 
Drug Class Generic name Effects on lipids Effects on glucose Impact on coronary artery disease 
Nucleos(t)ide Reverse 
Transcriptase 
Inhibitors: (NRTI) 
Abacavir(ABC) 
Azidothymidine 
Didanozine(ddl) 
Emtricitabine(FTC) 
Lamivudine(3TC) 
Stavudine(d4T) 
Tenofovir(TDF) 
 
TC↑ LDL↑ 
TC↑ LDL↑ 
Dyslipidemia++ 
Neutral 
Neutral 
Dyslipidemia + 
TC↓ LDL↓ 
 
No effect 
Insulin resistance+ 
Insulin resistance+ 
No effect 
No effect 
Insulin resistance+ 
No effect 
 
Increased risk of MI (controversial) 
No association  
No association 
No association 
No association 
No association 
No association 
 
Non-Nucleoside 
Reverse Transcriptase 
Inhibitors : (NNRTI) 
 
 
Efavirenz(EFV) 
Etravirine(ETR) 
Nevirapine(NVP) 
Rilpivirine(RPV) 
TC↑ LDL↑ 
Neutral 
HDL↑ 
Neutral 
No effect 
--- 
--- 
--- 
 
No association 
--- 
No association 
--- 
Protease Inhibitors: 
(PI) 
 
Ritonavir  
Amprenavir+ Ritonavir 
Fosamprenavir+Ritonavir 
 
Atazanavir+ Ritonavir 
Darunavir+ Ritonavir 
Indinavir 
 
Lopinavir+Ritonavir 
 
Nelfinavir 
Saquinavir 
Tipranavir+ Ritonavir 
Dyslipidaemia +++ 
Dyslipidaemia ++ 
Dyslipidaemia ++ 
 
Dyslipidaemia + 
Dyslipidaemia + 
Dyslipidaemia + 
 
Dyslipidaemia+++ 
 
Dyslipidaemia + 
Dyslipidaemia + 
Dyslipidaemia + 
 
Insulin resistance +++ 
Insulin resistance + 
Insulin resistance + 
 
Insulin resistance + 
Insulin resistance + 
Insulin resistance +++ 
 
Insulin resistance +++ 
 
Insulin resistance + 
Insulin resistance + 
Insulin resistance + 
Cumulative exposure increases risk for MI 
Cumulative exposure increases risk for MI 
Cumulative exposure increases risk for MI 
 
No association 
--- 
Controversial results 
 
Cumulative exposure increases risk for MI 
 
No association 
No association 
--- 
Integrase strand 
transfer inhibitors: 
(InSTI) 
Elvitregravir+ Cobicistat 
Raltegravir 
Dolutegravir 
Neutral 
Neutral 
Neutral 
 
No effect 
No effect 
No effect 
No association 
No association 
No association 
 
Entry inhibitors: (CC 
chemokine receptor 5 
antagonists) 
Maraviroc 
Enfuvirtide 
Neutral 
Neutral 
No effect 
No effect 
--- 
--- 
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Impact of diabetes on cardiovascular disease in human 
immunodeficiency virus 
Among the developped countries,an increasing proportion of the population is or will 
have to deal with diabetes mellitus: This growing civilization's disease turns to be a 
major public health issue and CVD is the leading cause of morbidity and mortality 
among diabetic patients [42].  
For HIV patients, age, BMI and sex remain the major risk factors for diabetes mellitus 
[43]. No  studies have been able to link HIV infection itself (in ART-naive patients) 
with diabetes mellitus, suggesting no increased risk of diabetes mellitus by HIV 
infection [44]; but increased rates of insulin resistance have been observed in ART-
naive HIV patients. The risk of diabetes in HIV is enhanced once patients start on 
ART [43–45].  We already mentionned adverse effects Protease inhibitors over lipids 
metabolism, but they also  reversibly increase insulin resistance,the risk of diabetes 
and subsequently the risk for CVD through the inhibition of glucose translocation 
through GLUT4 [46]. 
The NRTIs azidothymidine and stavudine appear to  have a direct effect on glucose 
metabolism through mitochondrial toxicity [47,48]. 
 A French systematic hospital database nationwide review has shown that the 
increased long-term risk for heart failure in HIV-infected compared with HIV-negative 
patients was independently associated with HIV +/- diabetes at 12-month follow-up 
[49]. These results advocate for the crutial importance of  glucose monitoring in 
patients on ART, especially in patients on PIs and older NRTIs. 
 
The prevalence of cardiovascular risks in HIV-infected 
patients in care in Croatia in 2015 
The specific datas concerning Croatia are arising from a cross-sectional study performed 
at the university hospital for infectious diseases “Fran Mihaljevic” Zagreb by Doctors 
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Vanja Romih Pintar and Pr.Dr Josip Begovac. Due to the fact that Croatia has a 
centralized system of treatment and care of persons infected with HIV, the datas 
collected there are therefore national.  
Objective: This analysis aimed at assessing and specifying the prevalence of 
cardiovascular risks factors among the HIV-infected population at the UHID Zagreb. 
Method: Over a period starting from June 2th 2014 to March 14th 2016, 310 consecutive 
HIV infected patients have been examined during a routine clinical follow-up visit . They 
were aged 40 to 79 years and were retracted from the study in case of acute illness or 
exacerbation of chronic illness at the time of theevaluation. Pregnant women were also 
excluded. All the next cardiovascular risks factors were systematically assessed: age, 
gender, race, total cholesterol, HDL cholesterol, triglycerides, systolic blood pressure, 
diastolic blood pressure, smoking, diabetes(blood glucose measurements), treated for 
high blood pressure (yes or no), past and current history of ART (particularly, duration of 
treatment including abacavir, indinavir and lopinavir (DAD)). Were also collected  CD4+ 
cell count, HIV viral load, family history of premature CVD, past medical history of CVD. 
Relying on the datas collected during this cross-sectional study, have been compared 
four cardiovascular disease  risk models: The Framingham risk score (FRS), the 
Pooled Cohort Atheroslcerotic CVD risk equations (ASCVD), the European 
Systematic Coronary Risk Evaluation Score (SCORE) and the Data Colletion on 
Adverse Effects of Anti-HIV Drug study (DAD). Patients have been categorized 
according to these four CVD risks models in  "high cardiovascular risk patients" and 
"non high cardiovascular risk patients". High risk: FRS-10y> 20%; SCORE-10y > 5%; 
ASCVD-10y > 7,5%; DAD -5y> 5%. 
Definitions 
CVD was considered present if a history of any of the following conditions existed on 
inclusion into the study: myocardial infarction, stable/unstable angina, invasive coronary 
artery procedure, carotid artery disease (symptomatic like transient ischemic attack or 
stroke, or >50 percent stenosis on angiography or ultrasound), stroke, peripheral artery 
disease, abdominal aortic aneurysm or other forms of clinical atherosclerotic disease (eg, 
renal artery disease).  
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Family history of premature cardiovascular events was considered present if the event 
occurred in a male first-degree relative <55 years or female first degree relative <65 
years.  
Diabetes mellitus was defined if at least two fasting plasma glucose levels were ≥7.0 
mmol/L, casual plasma glucose >11.1 mmol/L, or if patient had a history of diabetes 
treatment. 
Arterial hypertension was defined as systolic blood pressure >140 mm Hg and/or 
diastolic blood pressure >90 mm Hg (>135/85 mm Hg in diabetic patients) or taking     
antihypertensive drugs.  
Blood pressure was measured by the attending nurse using mercury 
sphygmomanometers. The patient was in a seated position; his or her arm was 
supported and flexed at the level of the heart. The stethoscope's bell was lightly pressed 
over the brachial artery just below the cuff's edge. The first knocking sound (Korotkoff) 
indicated the patient's systolic pressure and the disappearance of the knocking sound 
indicated diastolic pressure.  
Dyslipidemia was considered present if total cholesterol >6.2 mmol/L, HDL-cholesterol 
<1.03, or fasting triglycerides >2.26 mmol/L.  The modified updated National Cholesterol 
Education Program criteria were used  for the definition of metabolic syndrome: 
triglycerides of at least 1.7 mmol/L, HDL of 1.0 mmol/L or less in men and of 1.3 mmol/L 
or less in women, hypertension (systolic blood pressure >130 mm Hg or diastolic blood 
pressure >85 mm Hg), or use of antihypertensive medications and a glucose level at 
least 5.6 mmol/L or the diagnosis of diabetes.  
Body mass index was used as a surrogate for waist circumference. 
Results:  The global results indicate that the prevalence of major CVD risk factors is 
high in Croatia among the HIV-treated population in 2015. See details of independant 
risk factors below: 
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89%
11%
Men/Women ratio
Men
Women
 Figure1: Men/Woman ratio.  
In the studied population, men are overrepresented compared to the general 
population, they are 89%(figure 1). Male sex is a risk factor for cardiovascular 
diseases.
 
76,8
23,2
hypertension prevalence
normotensive patients
hypertensive patients
 
Figure 2: Hypertension prevalence. 
Hypertension prevalence is significantly high in the studied population, it reaches 23.2% (figure 2)  
According to European guidelines  of  the European Society of Cardiology and Europen 
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Atherosclerosis Society (ESC/EAS), hypertension is one if not the main leading independant risk of 
cardiovascular event (with age). 
Individual ART regimens:  
Figure 3: individual ART combination.
 
34%
12%
10%
5%
5%
4%
30%
Individual HAART combinations
Abacavir+Lamivudine/Efavirenz
Abacavir+Lamivudine/Lopinavir
Tenofovir+Emtricitabine/Efavire
nz
Tenofovir+Emtricitabine/Raltegr
avir
Zidovudine+Lamivudine/Nevira
pine
Tenofovir+Emtricitabine/Lopina
vir
others
 
 
10%
27%
58%
5%
HAART typology
2 NRTI+1 InSTI
2 NRTI+1 PI
2 NRTI+ 1 NNRTI
others
 Figure 4: ART Types. 
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As previously stated, some combinations are more susceptible to induce 
dyslipideamias and its consequence, atherosclerosis, than others:  
 27% of patients are having a PI-included ART combination (figure 4). 
 Among the 58% of patients treated with 2 NRTI+1NNRTI, only 10% are 
treated with nevirapine, others are treated with efavirenz which is less 
favorable regarding the lipids metabolism (figure 3). 
 
 
 
54%
46%
abacavir/other NRTI based HAART therapy
other NRTI based HAART
regimen
abacavir based HAART regimen
 Figure 5: abacavir based-/non abacavir-based regimens. 
Abacavir is suspected to be related to an elevated risk of myocardial infarctions[34]. 
 46% of the studied population have an abacavir-including regimen.(figure 5) 
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88%
12%
CD4+ cell count
CD4+ cell count > 350
CD4+ cell count ≤ 350
 Figure 6: CD4+ cell count. 
 Low CD4+ T cell count is a risk factor for cardiovascular disease events [50]  
In the studied population, 11.6% of patients have a low CD4+ cell count (figure 6). 
 
90%
10%
Plasma RNA HIV load
Viral load < 50 copies
Viral load ≥ 50 copies
 Figure 7: Viral load. 
A statistically significant relashionship exists between high  HIV RNA  load and low HDL-cholesterol 
[50,51] 
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 In the studied population, 10% of patients have a detectable viral load (figure 7). 
 
66%
34%
High risk cholesterol level
Cholesterol level ≤ 6,2 mmol/L
Cholesterol level > 6,2 mmol/L
 Figure 8: proportion of patients above/below the“high risk“ treshold of 6.2mmol/L of cholesterol (TC) 
Cholesterol level above 6.2mmol/L were found in 33.9% of individuals (figure 8). 
 
58%
42%
smokers:
non smokers
smokers
 
Figure 9: prevalence of smokers. 
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A very high prevelence of smokers (42.3%) is contained in the croatian HIV treated 
population (figure 9). Not only this population smokes more than the general population, but 
its body mass index (BMI) repartition is worrisome: 
 
non diabetic patients diabetic patients
 Figure 10: Prevalence of diabetes in HIV-infected population in care: 
In the studied population, 2.6% of patients exhibit diabetes (figure 10). 
 
6%
44%
38%
12%
Body Mass Index repartition
underweight: BMI < 20
Normal: 20 ≤ BMI ≤ 25
overweight: 25 < BMI ≤ 30
Obese: BMI > 30
 Figure 11: repartition of corpulence. 
 In the studied population, 37.7% of patients are overweight. 
 And 11.6% are obese (figure 11). 
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Cardiovascular disease  risk models
 Figure 12: Studied population screened by 4 risk models.The proportion of high and non-high scores 
are reported.  
Even though, the non HIV-specific models are not assessing the CVD risks with a 
similar range than the DAD does,  the global conclusion remains that the prevalence 
of major CVD risk factors is high in Croatia among the HIV-treated (figure 12). 
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79 81,6
21 18,4
treated for high blood pressure treated with lipid-lowering agents
patients already treated for CVD risk factors
no yes
 Figure 13:proportion of patients already undergoing treatment against CVD risk factors. 
In the studied population, 21% of patients are already treated for high blood 
pressure, and 18.4% are already treated with lipid-lowering agents (figure 13). 
 
not previous cardiovascular
event
myocardial infarction
bypass surgery
Stent placement
endarterectomy
Stroke
 Figure 14: Proportion of patients with past cardiovascular event. 
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In the studied population, 3.2% of patients suffered previous myocardial infarction, 
0.3% underwent bypass surgery, 2.3% stent placement, 1% endarterectomy and 1% 
suffered stroke. In total, 7.8% of patients had past cardiovascular event (figure 14). 
 
87%
13%
proportion of patients with family history of 
premature CVD.
no family history of premature
cardiovascular event
family history of premature
cardiovascular event
 Figure 15: proportion of patients with family history of premature cardiovascular event. 
In the studied population, 12.9% of patients have had a family history of premature 
cardiovascular event (figure 15).  
 
Discussion 
We found a high prevalence of different cardiovascular risk factors in HIV-infected 
persons in Croatia older than 40 years. 
 As previously stated, HIV-infected patients have metabolic abnormalities that make them 
susceptible to atherosclerosis. These abnormalities are caused by the combined effects 
of HIV infection itself, toxicities of specific antiretroviral therapies, as well as the 
traditional factors that increase atherosclerotic risk in the non–HIV-infected population: 
age, gender, smoking , overweight and obesity (Body mass index), systolic and diastolic 
blood pressure (hypertensive patients), previous cardiovascular event (the patient is then 
in secondary or tertiary prevention) total cholesterol, HDL-cholesterol and diabetes 
mellitus. 
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Assessing the exact level of influence of the HIV-infection as an independant factor and 
thus establishing equivalences with the non-infected population's risk models is 
challenging: 
Some studies have considered the intima-media thickening of carotide arteries(higher 
specificity with internal carotide arteries) as an efficient marker of atherosclerotic 
evolution and thus as a CVD predicting factor. Comparing the intima-media thickening of 
the carotide arteries corelated with different factors could therefore mesure the relative 
influence of the HIV infection as an independant risk factor compared to the other 
traditional CVD risks factors. Comparisons in between HIV population and controls (after 
adjustment for demographic and traditional CVD risk factors) have revealed that HIV-
infection induced intima-media thickening was similar to the effects associated with male 
gender, smoking status and diabetes mellitus [51]. These findings suggest that HIV 
infection can be considered as an independent risk factor for atherosclerosis similar to 
the level of risk associated with male gender, smoking status and diabetes. 
Among the HIV-infected population in care in Croatia in 2015, a high number of patients  
need interventions to reduce their cardiovascular disease risks. About one fifth to more 
than one third of patients, depending on the risk equation used, need intensive lifestyle 
modifications (cessation of smoking, diet, or weight loss) and lipid lowering therapy.  
Certain drugs used for HIV treatment, like lopinavir/ritonavir, indinavir/ ritonavir, 
amprenavir, and fosamprenavir have been associated with an increased risk for 
myocardial infarction [table 1]. Abacavir has also for long been correlated 
(controversially) with CVD. Guidelines recommend its cautious use in patients with a high 
CVD risks. However, in Croatia abacavir is frequently used due to the higher cost of 
tenofovir- based formulations compared to abacavir formulations. 
Another study, also based on the previous four prediction models, assessed the 
prevalence of eligibility for lipid lowering therapy among a HIV-infected population 
extended to Serbia (Belgrade and Zagreb combined HIV-treated population, forming 
a larger sample, very similar to the Croatian subgroup though) [53].  
The statins eligibility was assessed according to the 2013 American college of 
cardiology/American heart association (ACC/AHA) guidelines, the European AIDS 
Society Guidelines (EACS) and the European Atherosclerosis Society (ESC/EAS) 
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guidelines for CVD prevention in HIV infected patients on ART. On figure 16 we can 
notice a discrepancy between statins recommendations of the ACC/AHA (37.9%) and 
the EACS (21.3%) and ESC/EAS (25.6%), current lipid lowering therapies 
recommendations for eligibility should therefore be applied with caution in the HIV-
infected population. But still, this prevalence of lipid-lowering indication is significantly 
high in all considered models! 
 
88,7
74,4
62,1
21,3
25,6
37,9
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
European AIDS Clinical
society Guidelines
European Society of
Cardiology/E Atheroscl Soc
American College of
Cardiology/AHA
no Lipid-lowering therapy Eligible for lipid-lowering therapy
 
Figure 16: Prevalence of Lipid-lowering therapy eligibility. 
Conclusion 
The HIV-treated population of Croatia combines a constellation of significantly 
prevalent individual risk factors:  
  42% are current smokers! 
 23% are hypertensive. 
 34% have Hypercholesterolemia (>6.2 mmol/L).   
 38% of patients are overweight. 
 12% are obese.  
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  27% exhibit metabolic syndrome. 
 7.8% of patients suffered past cardiovascular event. 
 12.9%  patients have a family history of premature cardiovascular event. 
 21% of patients are already treated for high blood pressure. 
 18.4% are already treated with lipid-lowering agents. 
 46% of the studied population have an abacavir-including regimen. 
 10% of patients have a detectable viral load. 
 11.6% of patients have a low CD4+ cell count. 
 
The prevalence of compound major CVD risk factors is therefore high. All these 
factors synergetically interact as worthening the already cardiovascularly 
debilitating HIV infection per se. Preventing cardiovascular events in HIV-
infected persons in Croatia should be a priority. 
 
 
 Management of “high-risk for CVD” HIV-infected patients 
Antiretroviral treatment started on time 
Because HIV replication per se directly damages the myocardium, and can worsen 
any CVD risk models score, the European Aids Clinical Society (EACS) recommends 
to initiate ART even before CD4+ cell count drops below 500 cells/μL. 
Prevention of cardiovascular disease and lifestyle modification Cardiovascular risk in 
HIV patients needs to be evaluated before starting and 3 to 6 months after initiating a 
ART regimen. Of note, a careful selection of antiretroviral combination, (provided 
unlimited access to the least detrimental drugs regarding lipid and glucose 
metabolism) is of very first importance. Because cardiovascular risk management is 
necessary to counter balance the increased cardiovascular morbidity in this HIV-
infected population, the interventions for cardiovascular risk reduction should follow 
those of the general population considered at “high risk of CVD” by any CVD 
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assessment models or the specific HIV-infected patients oriented CVD risk model like 
the DAD(R) model (see www.cphiv.dk/tools.aspx).   
The modifiable risk factors should be aggressively handled towards maximum 
reduction: smoking status, high blood pressure, diabetes, excessive BMI, 
dyslipidemias; drug treatments being reserved for the subgroups where benefits are 
considered to outweigh potential harm. 
Dyslipidemias management 
Even though, the increased risk of CVD by HIV infection itself has yet to be reflected 
in conventional risk calculations, this increased risk is a valuable argument for lipid-
lowering treatment in dyslipidemic HIV-infected patients even if this risk can be 
overestimated by conventional risk calculation [53]. Appropriate use of lipid-lowering 
drugs in these patients requires a thorough attention towards multiple drugs 
interactions between HIV therapies and commonly used cardiovascular drugs. 
The problem with statin therapy in patients receiving antiretroviral therapy is not lack 
of efficacy in reducing LDL-C level, but drug interactions with PIs and NNRTIs. The 
PIs inhibit cytochrome P450 (CYP) 3A4 isoenzymes, which metabolize some statins: 
Drug interactions that raise statins level, leading to potential hepatotoxicity, myopathy 
and rhabdomyolysis are then of particular concern for HIV-infected patients. 
Simvastatin and lovastatin are metabolized by CYP 3A4, thus, simvastatin or 
lovastatin should not be used by PI treated patients. Atorvastatin is less extensively 
metabolized by CYP 3A4, so a carefully monitored use is possible. Pravastatin 
undergoes sulfurylation and then bypasses CYP450 isoenzymes catabolic pathway. 
However, combined with saquinavir/ritonavir, atorvastatin was increased almost 2-
fold and pravastatin was decreased by half (simvastatin was increased more than 30-
fold in this study)[54].So a cautious introduction of these two statins, atorvastatin and 
pravastatin is mandatory, no matter their relatively less sensible pharmacokinetic 
properties regarding CYP450 isoenzymes inhibitors. 
Rosuvastatin is a very potent statin with a relatively lower potential for drug 
interactions. But some PIs increase rosuvastatin blood levels via a non-CYP3A4-
related mechanism: Rosuvastatin maximum concentration was increased 4.7-fold by 
lopinavir/ritonavir [55] and 6-fold by atazanavir/ritonavir (most likely by increasing 
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rosuvastatin's oral bioavailability) [56]. Thus, high-dose rosuvastatin should be 
avoided by patients receiving these PIs. Interestingly no change in rosuvastatin 
concentration was observed with fosamprenavir/ritonavir [57]. 
 
In general, the potential for inhibition of statin metabolism is as follows: simvastatin 
and lovastatin > atorvastatin and rosuvastatin >> pravastatin. 
 
Non-nucleoside reverse transcriptase inhibitors on the other hand are inducers of 
CYP 450 and can potentially reduce drug levels of drugs. 
Efavirenz lowers simvastatin (and likely lovastatin) level by 60%, atorvastatin activity 
by 34%, and, paradoxically, pravastatin level by 40% (Pravastatin is cleared by the 
kidney so intuitively it shouldn’t be influenced by drug interactions inhibiting CYP450 
isoenzymes [57]. Higher levels of such statin drugs should be needed, but there is 
potential risk of “overdose” and would put patients at risk for rhabdomyolysis. 
Delavirdine inhibits hepatic cytochrome P450 metabolism [54]. Thus, delavirdine 
increases statin levels and the risk of statin-related adverse effects similarly to PIs.  
 
Modification of antiretroviral therapy 
 
In HIV patients on ART who have had a newly developed a cardiovascular event or 
developed a substantial increase in cardiovascular risk, ART modification may 
represent an option to replace antiretroviral drugs with a risk of enhancing 
cardiovascular risk by more metabolic-friendly ones. Treatment modifications would 
include replacement of PI (especially ritonavir-boosted PI-based therapy) with non-
nucleoside reverse transcriptase inhibitors (NNRTI), raltegravir or by another PI with 
less metabolic disturbances. Other modification could be to consider replacing 
stavudine, azidothymidine, or abacavir with tenofovir (see Table 1) or use a NRTI 
sparing regimen. 
But a change in ART regimen in patients with an undetectable viral load and 
otherwise tolerating their current regimen well, shouldn’t be an option for the only aim 
at preventing potential metabolic complications. 
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Niacin  
In HIV-infected patients, niacin can decrease TG up to 32%, non HDL-cholesterol by 
9% and up to 19% and increase HDL-cholesterol by 3% to 15% [58,59]. Because it 
can cause insulin resistance even in nondiabetic patients [58] niacin has been 
avoided as a first line therapy for patients using PIs, but studies in diabetic subjects 
suggest that this insulin resistance effect is only mild in control of glycaemia for these  
diabetic patients [61,62]. 
 
Fibrate  
In HIV-infected patients, fibrates are not as potent as statins in preventing 
cardiovascular disease. Although less effective in lowering LDL-cholesterol, the 
ability of fibrates to increase HDL-cholesterol and to lower triglycerides levels justify 
their combined use with statins. Studies with HIV-1 patients treated with PI-based 
therapy and fibrates, including gemfibrozil, bezafibrate or fenofibrate, showed a 
significant reduction in the concentration of TC, TG and hypertriglyceridemia [63-65]. 
Fibrates appear as a suitable alternative for the treatment of dyslipidemia associated 
with HIV, especially in the presence of hypertriglyceridemia. The association between 
fibrates and statins has been used with relative safety in the general population 
except for the combination of statins and gemfibrozil (gemfibrozil is a potent CYP450 
system inhibitor), which is not recommended [65-67]. The association has shown 
positive results in HIV-associated dyslipidemia, particularly for the 
pravastatin/fenofibrate combination which appeared safe and has promoted a 
significant improvement in lipid parameters [68,69]. However, Periodic monitoring of 
serum creatinine, creatine kinase, and transaminases should be performed for the 
use of fibrates [64,65,67]. 
 
Fish oil 
Liver cod oil and other fish oils containing eicosapentaenoic acid (EPA) and 
Docosahexaenoic acid (DHA) [omega-3 fatty acids] have strong anti-inflammatory 
and anti-platelets properties [70,71]. They restore the ratio omega-3/omega-6; ideally 
around 1:5 but unfortunately more often around 1:20 in the nowadays occidental 
(inappropriate) diet … The rapid evolution of human diet away from a 1:5 omega-3 
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over omega-6 ratio, such as during the pre-intensive agriculture era has been too fast 
for human metabolism to adapte to such rapid  changes [72]. This is commonly 
believed to be the reason why modern diets are correlated with many inflammatory 
disorders. It is now understood that inflammation is a major component in the 
pathogenesis of atherosclerosis [73]. Consumption of omega-3 fatty acids from 
marine sources lowers markers of inflammation in the blood such as C-reactive 
protein, interleukin 6, and TNF alpha [74]. HIV-infected patients consuming fish oil 
supplements have efficiently reduced their triglycerides levels [71] and associated 
with fenofibrate, the results on TG are additive. 
 
Extra virgin olive oil 
Even if extra virgin olive oil’s fatty acids profile is quite neutral over the omega-
3/omega-6 ratio, it contains a phenolic fraction that subsides inflammation. A 
randomized, crossover, controlled trial including 39 HIV-positive male participants 
using ART,  has been able to show that extra virgin olive oil (compared to refined 
olive oil) lowers high-sensitivity C-reactive protein[75]. Other inflammatory and 
biological markers were monitored (interleukin-6, fibrinogen, total cholesterol, LDL 
cholesterol, HDL cholesterol, triglycerides, malondialdehyde, glutathione-peroxidase, 
superoxide dismutase, oxidized LDL and von Willebrand factor) but extra virgin olive 
oil only lowered erythrocyte sedimentation rate (ESR) and high-sensitivity C-reactive 
protein (hsCRP). Anyway, in participants using lopinavir/ritonavir, ESR and hsCRP 
concentrations decreased 62% and 151%, respectively, after extra virgin olive oil 
administration suggesting that such a supplementation could be beneficial to hinder 
inflammatory and oxidative subclinical processes always present in HIV-infection. 
Even successfully treated HIV-infected patients may still have an increased 
cardiovascular risk, which might be related to inflammation and dyslipidemia induced 
by HIV and/or antiretroviral therapy. A study suggests that in patients with 
undetectable viral load, there is a significant association between markers of 
inflammation and serum levels of cholesterol and triglycerides as well as the 
cholesterol/HDL-cholesterol ratio [76]. 
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